(3.235.191.87) 您好!臺灣時間:2021/05/13 04:35
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:威迪雅
研究生(外文):Debora Arny Widowati
論文名稱:蜂王漿中癸烯酸的抗發炎活性分析及研究
論文名稱(外文):The Anti-Inflammatory Activity of 10-HDA from Royal Jelly
指導教授:彭及忠
指導教授(外文):Chi-Chung Peng 彭及忠
學位類別:碩士
校院名稱:國立虎尾科技大學
系所名稱:生物科技研究所
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
論文出版年:2014
畢業學年度:102
語文別:英文
論文頁數:49
中文關鍵詞:癸烯酸抗發炎WiDr細胞大腸癌細胞及細胞激素
外文關鍵詞:10-hydroxy-2-decenoic acid (10-HDA)Anti-inflammatoryWiDr cellsColon cancer cellCytokines
相關次數:
  • 被引用被引用:0
  • 點閱點閱:499
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
蜂王漿已被證明具有免疫調節活性,尤其是在它的蛋白質成分。然而,尚未有研究表明蜂王漿之脂肪酸對免疫系統的影響。蜂王漿之主要脂肪酸為癸烯酸,且已被證實具有抗發炎效果。在本研究中,探討癸烯酸作用於WiDr細胞的細胞存活率及主要發炎激素之分泌。利用不同濃度之癸烯酸作用於WiDr細胞,探討癸烯酸對其細胞之作用。癸烯酸在高劑量 (5 mM) 下對WiDr細胞具有毒性,在低劑量下 (2和3 mM)則不具細胞毒性,並對IL-8,IL-1β,與TNF-α有顯著的抑制效果。並且顯著誘導IL-1受體拮抗劑之分泌。體外試驗結果顯示,在低劑量癸烯酸下,具有顯著的抗發炎效果,可能具有成為免疫調節藥物的潛力。

Royal jelly (RJ) has been shown to possess immunomodulatory activity, especially its protein components. However, almost nothing is known about influence of RJ fatty acids on the immune system. The anti-inflammatory effect of 10-hydroxy-2-decenoic acid (10-HDA), a major fatty acid in RJ was investigated. In this study, we studied the effect of 10-HDA on the cell viability and the release of important inflammatory cytokines from WiDr cell. To investigate the effect of 10-HDA, we treated WiDr human colon cancer cells with various concentration of 10-HDA. The higher dose (5 mM) of 10-HDA has cytotoxic effect on WiDr, it could directly kill the colon cancer cells. A lower dose of 10-HDA (2 and 3 mM), although non-cytotoxic, but it has significant inhibition of the pro-inflammatory cytokines. The cytokines that inhibited are interleukin (IL)-8, IL-1β, and tumor necrosis factor-alpha (TNF-α). It also significantly induces receptor antagonist cytokine (IL-1ra). 10-HDA inhibited the cell growth of WiDr in a dose-dependent manner. These data suggest that a non-toxic concentration of 10-HDA has a significant effect on the in vitro growth of WiDr cells, and may have value as a therapeutic immunomodulatory property.


English Abstract ……………………………………………………………… i
Chinese Abstract …………………………………………………………… ii
Acknowledgements or Preface …………………………………………………………… iii
Table of Contents …………………………………………………………… iv
List of Tables …………………………………………………………… v
List of Figures …………………………………………………………… vi
Chapter 1 Literature Review……………………………………… 1
1.1 Definition of Royal Jelly (RJ) and 10-Hydroxy-2-Decenoic Acid (10-HDA) from RJ……………………………… 1
1.2 Health Properties of RJ and 10-HDA from RJ…………… 3
1.3 Inflammatory Bowel Disease (IBD)………………………… 5
1.4 Cytokines/Chemokine on IBD……………………… 7
1.4.1 Interleukin-8 (IL-8)……………………………… 8
1.4.2 Interleukin-1 Receptor Antagonist (IL-1ra)…………… 9
1.4.2.1 Gastrointestinal tract and inflammatory bowel disease……… 9
1.4.3 Interleukin-1 Family (IL-1β)……………………… 10
1.4.4 Tumor Necrosis Factor-α (TNF-α) …………………… 11
1.5 Anti-Inflammation Therapeutic Effect on IBD………… 12
1.6 Human Colon Adenocarcinoma Cell (WiDr cell)………… 13
1.7 Patents Search…………………………………………… 14
1.7.1 10-Hydroxy-2-Decenoic Acid Patents…………………… 14
Chapter 2 Materials and Methods……………………………………… 15
2.1 Experimental Procedure…………………………………… 15
2.2 Preparation of 10-HDA from Royal Jelly…………………… 16
2.2.1 Extraction of royal jelly with ethanol………………… 16
2.2.2 Quantitative analysis of 10-HDA content…………………… 16
2.3 Cell viabilities assay………………………………………… 16
2.4 Enzyme-linked immunosorbent assay (ELISA) …………… 17
2.5 Statistical analysis………………………………………… 18
Chapter 3 Results……………………………………………… 19
3.1 Preparation of 10-HDA from royal jelly…………………… 19
3.2 10-HDA inhibits growth of WiDr cells…………………… 19
3.3 10-HDA inhibits IL-8, IL-1β, and TNF-α production in WiDr cells……………………………………………………… 20
3.4 10-HDA induces IL-1ra production in WiDr cells… 20
Chapter 4 Discussions…………………………………… 21
Chapter 5 Conclusion………………………………………………… 24
References ……………………………………………………………… 25
Extended Abstract ……………………………………………………………… 40
Curriculum Vitae ……………………………………………………………… 49


[1] Moritz, R. F. A., Southwick, E. E., 1992, Bees a superorganisms, An evolutionary reality, first ed., Springer-Verlag, Berlin.
[2] Draper, R. W., 2013, Royal jelly, http://www.draperbee.com/info/royaljelly.htm, [September 30th, 2013].
[3] Simuth, J., Bilikova, K., Kovacova, E, 2004, Royal Jelly protein as a tool for development of functional ingredients for health, Apimondia Journal.
[4] Elkins, R., 1996, Bee Polen, Royal Jelly, Propolis and Honey, Woodland publishing.
[5] Kim, J. Y., Lee, J. S., 2010, Quantitative analysis of trans-10-hydroxy-2-decenoic acid in royal jelly product purchased in USA by high performance liquid chromatography, J. of Apicultur. Sci., Vol.54 No.1 77-85.
[6] Lercker, G., et al., 1981, Components of royal jelly: I. Identification of the organic acids, Lipids 12:912–919.
[7] Plettner, E., Slessor, K. N.,Winston, M. L., 1998, Biosynthesis of mandibular acids in honeybees (Apis mellifera): de novo synthesis, route of fatty acid hydroxylation and caste selective b-oxidation, Insect Biochem Mol Biol 28:31–42.
[8] Ferioli, F. M., Marcazzan, G. L., Carboni, M. F., 2007, Determination of (E)-10-hydroxy-2-decenoic acid content in pure royal jelly: a comparison between a new CZE method and HPLC, J. Sep. Sci 30(7): 1061-1069.
[9] Antinelli, J.-F., et al., 2003, Evaluation of (E)-10-hydroxy-2-decenoic acid as a freshness parameter for royal jelly, Food Chem. 80,85-89.
[10] Kim, J. K., Son, J. H., Kim, K. H., 1989, A survey of analyzing in gradient of royal jelly in Korea on majoring 10-HDA, Korean J. Apic., 4,34-40.
[11] Zhou, J., Zhao, J., Yuan, H., et al., 2007, Comparison of UPLC and HPLC for determination of trans-10-hydroxy-2-decenoic acid content in royal jelly by ultrasound-assisted extraction with internal standard, Chromatographia, 66, 185-190.
[12] Bloodworth, B. C., Harn, C. S., Hock, C. T., 1995, Liquid chromatographic determination of trans-10-hydroxy-2-decenoic-acid content of commercial products containing royal jelly, J. AOAC Int. 78, 1019-1023.

[13] Mărghitaş, L. A., 2008, Produsele apicole şi principalele lor insuşiri terapeutice, In: Albinele şi produsele lor. L. A. Mărghitaş, second ed., pp. 280-378, Ceres, Bucharest.
[14] Izuta, H., Chikaraishi, Y., Shimazawa, M., et al., 2009, 10-Hydroxy-2-decenoic Acid, a Major Fatty Acid from Royal Jelly, Inhibits VEGF induced Angiogenesis in Human Umbilical Vein Endothelial Cells, Evid. Based Complement. Alternat. Med., 6(4), 489-494.
[15] Bincoletto, C., Eberlin, S., Figueiredo, C. A., et al., 2005, Effects produced by Royal Jelly on haematopoiesis: relation with host resistance against Ehrlich ascites tumour challenge. Int. Immunopharmacol., 5(4), 679-688.
[16] Tamura, T., Fujii, A., Kuboyama, N., 1987, Antitumor effects of royal jelly (RJ), Nippon Yakurigaku Zasshi, 89(2), 73-80.
[17] Townsend, G. F., Morgan, J. F., Hazlett, B., 1959, Activity of 10-hydroxydecenoic acid from Royal Jelly against experimental leukaemia and ascitic tumours, Nature, 183(4670), 1270-1271.
[18] Kohno, K., Okamoto, I., Sano, O., et al., 2004, Royal jelly inhibits the production of pro-inflammatory cytokines by activated macrophages, Biosci. Biotechnol. Biochem.,68(1), 138-45.
[19] Fujii, A., Kobayashi, S., Kuboyama, N., et al., 1990, Augmentation of wound healing by royal jelly (RJ) in streptozotocin-diabetic rats, Japanese J. of Pharmacol., 1990, 53, 331–337.
[20] Satomi, K.M., Okamoto, I., Ushio, S., et al., 2004, Identification of a Collagen Production-promoting Factor from an Extract of Royal Jelly and Its Possible Mechanism, Biosci. Biotechnol. and Biochem., 68(4), 767-773.
[21] Vucevic, D., et al., 2007, Fatty acids isolated from royal jelly modulate dendritic cell-mediated immune response in vitro, Int. Immunopharmacol., 7, 1211–1220.
[22] Gasic, S.,et al., 2007, Evaluation of the immunomodulatory activities of royal jelly components in vitro, Immunopharmacol. and Immunotoxicol., 29, 521–536.
[23] Watanabe, K., Shinmoto, H., Kobori, M., et al., 1996, Growth stimulation with honey royal jelly DIII protein of human lymphocytic cell lines in a serum-free medium, Biotechnol. Tech., 10 (12), 959-962.
[24] Watanabe, H. S., Shinmoto, H., Masuko, K., et al., 1998, Stimulation of cell growth in the U-937 human myeloid cell line by honey royal jelly protein, Cytotechnol., 26:23–27.

[25] Kimura, M., Kimura, Y., Tsumura, K., et al., 2003, 350-kDa royal jelly glycoprotein (apisin), which stimulates proliferation of human monocytes, bears the beta1-3galactosylated N-glycan: Analysis of the Nglycosylation site, Biosci. Biotechnol. Biochem., 67, 2055–2058.
[26] Okamoto, I., Taniguchi, Y., Kunikata, T., et al., 2003, Major royal jelly protein 3 modulates immune responses in vitro and in vivo, Life Sci., 73(16), 2029-2045.
[27] Romano, C., Famiani, A., Gallizzi, R., Comito et al., 2008, Indeterminate colitis: a distinctive clinical pattern of inflammatory bowel disease in children, Pediatrics 122 (6): e1278–1281.
[28] Lin, W. –W., Karin, M., 2007, A cytokine-mediated link between innate immunity, inflammation, and cancer, J. Clin. Invest., 117(5):1175-1183.
[29] Coussens, L. M., Werb, Z., 2002, Inflammation and cancer, Nature 420:860-867.
[30] Shacter, E., Weitzman, S. A., 2002, Chronic inflammation and cancer, Oncology 16:217-226.
[31] Hussain, S. P., Hofseth, L. J., Harris, C. C., 2003, Radical causes of cancer. Nat. Rev. Cancer 3:276-285.
[32] Fox, J. G., Wang, T. C., 2007, Inflammation, atrophy, and gastric cancer, J. Clin. Invest.117:60-69.
[33] Dobrovolskaia, M. A., Kozlov, S. V., 2005, Inflammation and cancer: when NF-kappaB amalgamates the perilous partnership, Curr. Cancer Drug Targets 5:325-344.
[34] de Visser, K. E., Eichten, A., Coussens, L. M, 2006, Paradoxical roles of the immune system during cancer development, Nat. Rev. Cancer. 6:24-37.
[35] Papadakis, K. A., Targan, S. R., 2000, Role of cytokines in the pathogenesis of inflammatory bowel diseases, Annu. Rev. Med. 51:289–298.
[36] Hanauer, S. B., 2006, Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities, IBD Vol. 12(5):S3-S9.
[37] National Institute of Diabetes and Digestive and Kidney Diseases, 1994, Digestive Diseases in the United States: Epidemiology and Impact, Washington, DC: US Government Printing Office. NIH publication 94-1447.

[38] Crohn''s & Colitis Foundation of America, 2005, Living with Crohn''s Disease [educational brochure]. Available at: http://www.ccfa.org. Accessed August 19, 2005.
[39] Crohn''s & Colitis Foundation of America, 2005, Living with Ulcerative Colitis [educational brochure]. Available at: http://www.ccfa.org. Accessed August 19, 2005.
[40] Sandler, R. S., Loftus, E. V. Jr., 2004, Epidemiology of inflammatory bowel disease. In: Sartor, R. B., Sandborn, W. J., eds. Kirsner''s Inflammatory Bowel Diseases, 6th ed. Philadelphia, PA: WB Saunders 245–262.
[41] Krishnan, A., Korzenik, J. R., 2002, Inflammatory bowel disease and environmental influences. Gastroenterol. Clin. North. Am. 31:21–39.
[42] Loftus, E. V. Jr, Sandborn, W. J., 2003, Epidemiology of inflammatory bowel disease. Gastroenterol. Clin. North. Am. 31: 1–20.
[43] CORDIS, 2013, Opening up new pathways for treating inflammatory bowel disease, http://cordis.europa.eu/news/rcn/35962_en.html, [January 25th, 2014].
[44] Ferrero-Miliani, L., Nielsen, O. H., Andersen, P. S., Girardin, S. E., 2007, Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation, Clin. Exp. Immunol.,147 (2):227-235.
[45] Abbas, A. B., Lichtman, A. H., 2009, Ch.2 Innate Immunity, In Saunders (Elsevier). Basic Immunology. Functions and disorders of the immune system (3rd ed.).
[46] Thun, M. J., Namboodiri, M. M., Heath, C. W. Jr., 1991, Aspirin use and reduced risk of fatal colon cancer, N. Engl. Med. 325, 1593-1596.
[47] Balkwill, E., Mantovani, A., 2001, Inflammation and cancer: back to Virchow?, Lancet 357, 539-545.
[48] Baggiolini, M., Walz, A., Kunkel, S. L., 1989, Neutrophil-activating peptide-1/interleukin-8, a novel cytokine that activates neutrophils, J. Clin. Invest. 84:1045-1049.
[49] Mukaida, N., Shiroo, M., Matsushima, K., 1989, Genomic tructure of the human monocyte-derived neutrophil chemotactic factor IL-8, J. Immunol. 143:1366-1371.
[50] Eckmann, L., Jung, H. C., Schurer-Maly, C., et al., 1993, Differential cytokine expression by human intestinal epithelial cell lines: regulated expression of interleukin-8, Gastroenterol. 105:1698-1707.

[51] Nguyen, H. C., Ohno, Y., Reinecker, H. C., et al., 1993, CaCo-2 cells synthesize and secrete increased amounts of interleukin-8 after stimulation by PMA and IL-1, Gastroenterol. 104:A754.
[52] Gross, V., Andus, T., Daig, R., et al., 1994, Protein tyrosine kinase activation is required for induction of IL-8 by IL-1 or TNF in an intestinal epithelial cell line (HT-29), Gastroenterol. 106:A694.
[53] Daig, R., Andus, T., Aschenbrenner, E., et al., 1996, Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease, Gut 38:216-222.
[54] Mukaida, N., Ketlinsky, S. A., Matsushima, K., 2003, Interleukin-8 and other CXC chemokines, In: The Cytokine Handbook, 4th Edition, pp. 1049-1081, (A. W. Thomson, M. T. Lotze), Elsevier Science Ltd., London.
[55] Lee, L. E, Hellendall, R. P., Wang, Y., et al., 2000, IL-8 reduced tumorigenicity of human ovarian cancer in vivo due to neutrophil infiltration, J. Immunol. 164, 2769-2775.
[56] Arend, W. P., Evans, C. H., 2003, Interleukin-1 receptor antagonist [IL-1F3], In: The Cytokine Handbook, 4th Edition, pp. 669-708, (A. W. Thomson, M. T. Lotze), Elsevier Science Ltd., London.
[57] Nicklin, M. J., Hughes, D. E., Barton, J.L., et al., 2000, Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene, I, Exp. Med. 191, 303-312.
[58] Horai, R., Saijo, S., Tanioka, H., et al., 2000, Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist deficient mice, Exp. Med. 191, 313-320.
[59] Kuboyama, S., 1998, Increased circulating levels of interleukin-1 receptor antagonist in patients with inflammatory bowel disease, Kurume Med. J. 45, 33-37.
[60] Dionne, S., D''Agata, I.D., Hiscott, J., et al., 1998, Colonic explant production of IL-l and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD), Clin. Exp. ImmunoL 112, 435-442.
[61] Nishiyama, T., Mitsuyama, K., Toyonaga, A., et al., 1994, Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease, Digestion 55, 368-373.
[62] Ferretti, M., Casini-Raggi, V., Pizarro, T. T., et al., 1994, Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis, J. Clin. Invest. 94, 449-453.

[63] Iwagaki, H., Hizuta, A., Tanaka, N., 1997, Interleukin-1 receptor antagonists and other markers in colorectal cancer patients, Scand. Gastroenterol. 32, 577-581.
[64] Ito, H., Miki, C., 1999, Profile of circulating levels of interleukin-1 receptor antagonist and interleukin-6 in colorectal cancer patients, Scand. Gastroenterol. 34, 1139-1143.
[65] Dinarello, C. A., 2003, Interleukin-1 Family [IL-1 F1, F2], In: The Cytokine Handbook, 4th Edition, pp. 643-668, (A. W. Thomson, M. T. Lotze), Elsevier Science Ltd., London.
[66] Zheng, H., et al., 1995, Resistance to fever induction and impaired acute-phase response in interleukin-1β deficient mice, Immunity 3, 9-19.
[67] Fantuzzi, G., et al., 1997, Response to local inflammation of IL-1β converting enzyme-deficient mice, J. Immunol. 158, 1818-1824.
[68] Fantuzzi, G., et al., 1997, Physiological and cytokine responses in interleukin-1β-deficient mice after zymosan-induced infammation, Am. J. Physiol. 273, R400-R406.
[69] Alheim, K., et al., 1997, Hyperresponsive febrile reactions to interleukin (IL) lα and IL-1β, and altered brain cytokine mRNA and serum cytokine levels, in IL-1β -deficient mice, Proc. Natl. Acad. Sci. USA 94, 2681-2686.
[70] Wang, H., Czura, C. J., Tracey, K. J., 2003, Tumor necrosis factor, In: The Cytokine Handbook, 4th Edition, pp. 837-860, (A. W. Thomson, M. T. Lotze), Elsevier Science Ltd., London.
[71] Lienard Lienard, D., Ewalenko. P., Delmotte. J. J., et al., 1992, High-dose recombinant tumor necrosis factor r in combination with interferon 7 and melphalan in isolation perfusion of the limbs for melanoma and sarcoma, J. Clin. Oncol. 10, 52-60.
[72] North, R. J., Havell, E.A., 1988, The antitumor function of tumor necrosis factor (TNF). II. Analysis of the role of endogenous TNF in endotoxin-induced hemorrhagic necrosis and regression of an established sarcoma, J. Exp. Med. 167, 1086-1099.
[73] Duerksen-Hughes, R. J., Day, D. B., Laster, S. M., et al., 1992, Both tumor necrosis factor and nitric oxide participate in lysis of simian virus 40-transformed cells by activated macrophages, J. Immunol. 149, 2114-2122.
[74] Tracey, K. J., Cerami, A., 1994, Tumor necrosis factor: a pleiotropic cytokine and therapeutic target, Annu. Rev. Med. 45, 491-503.

[75] Estrada, C., Gomez, C., Martin, C., et al., 1992, Nitric oxide mediates tumor necrosis factor-a cytotoxicity in endothelial cells, Biochem. Biophys. Res. Commun. 186,475-482.
[76] Sato, Y., Koshita, Y., Hirayama, M., et al., 1996, Augmented antitumor effects of killer cells induced by tumor necrosis factor gene-transduced autologous tumor cells from gastrointestinal cancer patients, Hum. Gene Ther. 7, 1895-1905.
[77] Thomson, A. M., 1997, Neuroscience. More than just frequency detectors?, Science 275, 179-180.
[78] Buck, C., Digel, W., Schoniger, W., et al., 1990, Tumor necrosis factor-a, but not lymphotoxin, stimulates growth of tumor cells in hairy cell leukemia, Leukemia 4, 431-434.
[79] Popivanova B. K., Kitamura K., Wu Y., et al., 2008, Mukaida Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis, J. Clin. Invest., 118, pp. 560–570.
[80] Tu, S., Bhagat, G., Cui, G., et al., 2008, Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice, Cancer Cell, 14, pp. 408–419.
[81] Pikarsky, E., Porat, R. M., Stein, I., et al., 2004, NF-kappaB functions as a tumour promoter in inflammation-associated cancer, Nature, pp. 461–466.
[82] Podolsky, D. K., 2002, Inflammatory bowel disease, N. Engl. J. Med., 347:417-429.
[83] Kim, E. J. et al., 2005, Induction of apoptosis by the aqueous extract of Rubus coreanum in HT-29 human colon cancer cells, Nutrition 21, 1141–1148.
[84] Noguchi, P., Wallace, R., Johnson, J., et al., 1979, Characterization of the WIDR: a human colon carcinoma cell line, In Vitro, 15(6):401-408.
[85] Chen, T. R., Drabkowski, D., Hay, R. J., et al., 1987, WiDr is a derivative of another colon adenocarcinoma cell line, HT-29, Cancer Genet. Cytogenet., 27(1):125-134.
[86] Tracey, K. J., Vlassara, H., and Cerami, A., 1989, Cathecin / tumor necrosis factor, Lancet 20, 1122-1126.
[87] Flynn, J. L., Goldstein, M. M., Chan, J., et al., 1995, Tumor necrosis factor-α is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2, 561-572.

[88] Sirois, M. G., Plante, G. E., Braquet, P., and Sirois, P., 1990, Tumor necrosis factor primes the effects of platelet-activating factor on rat vascular permebility. J. Lipid Mediat. 2:109-117.
[89] Gallucci, R. M., Simeonova, P. P., Matheson, J. M., et al., 2000, Impaired cutaneous wound healing in interleukin-6-deficient and immunosuppressed mice. FASEB J. 14:2525-2531.
[90] Feldmann, M., Brennan, F. M., and Maini, R. N., 1996, Rheumatoid arthritis, Cell 85:307-310.
[91] Mend, W.P., 1993, Interleukin-1 receptor antagonist, Adv. lmmunol. 54, 167-227.
[92] Mend, W.P., Welgus, H.G., Thompson, R.C. and Eisenberg, S.P., 1990, Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J. Clin. Invest. 85, 1694-1697.


QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔